Full-Time

Territory Manager - Cardiac & Peripheral Intervention

Multiple Teams

Posted on 8/7/2025

Merit Medical Systems

Merit Medical Systems

1,001-5,000 employees

Manufactures disposable medical devices for interventions

No salary listed

Walsrode, Germany

Remote

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Education and experience equivalent to a related Bachelor's Degree.
  • A minimum of three years of direct sales experience, preferably in selling medical products.
  • Ability to communicate effectively with and to understand the needs of others in a sales relationship.
  • A high degree of personal motivation and drive to achieve personal and professional goals.
  • Excellent oral presentation skills and the ability to think quickly to apply facts in analysing a problem and explaining that answer to a group of medical technicians and clinicians.
  • Ability to learn the usage of medical equipment and to identify and explain possible improvements in usage.
  • Ability to work effectively as a team member to achieve organization goals.
  • Ability to utilize business mathematics to figure percentages, prepare financial and sales information.
  • A high degree of personal organization skills, including the ability to record and report information and to document work performed.
  • Ability to work independently with a minimum of supervision.
  • Ability to travel extensively and work long hours to achieve goals, as required.
  • Demonstrated computer skills preferably spreadsheets, word processing, database and other applicable software programs.
  • Fluent in German and English.
Responsibilities
  • Meeting regularly with clients and accounts to present and demonstrate Merit products and to explain their benefits.
  • Identifying potential customers and introducing them to the products offered by Merit.
  • Maintaining contacts with clients to monitor their satisfaction with products.
  • Identifying opportunities to improve customer satisfaction with products.
  • Preparing customized drawings for clients needing custom kits or manifolds.
  • Preparing and submitting pricing contracts to clients for products.
  • Following up with clients to identify opportunities to increase sales volume and profitability.
  • Resolving problems with clients regarding manufacturing or delivery problems, if they occur.
  • Coordinates with other Merit marketing and sales staff to ensure that the right products are shipped to customers on a timely basis and in the amount required, to stay informed about new products provided by Merit, and to provide feedback from customers about product needs and possible innovations.
  • Makes decisions within approved authorization limits regarding product pricing to optimize sales volume and profitability.
  • Prepares a monthly report summarizing monthly sales results achieved, contacts made, needs for change in products and suggestions for improvement in Merit's procedures.
  • Participates in a variety of sales training and planning meetings to learn about new products and marketing promotions, and to share information about sales goals.
  • Maintains a high level of knowledge about Merit and competitor products and their advantages and disadvantages.
  • Sets and achieves personal performance goals for sales volume, new contacts made, new client sales and other related sales results achieved.
  • Participates as a member of the Merit sales team to improve Merit's ability to increase market share by identifying ways to increase product quality and customer satisfaction.
  • Travels by car, airplane, bus, etc. to perform sales duties with clients.
  • Performs a variety of other sales related duties, as required.
Merit Medical Systems

Merit Medical Systems

View

Merit Medical Systems develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. These one-time-use devices are used during procedures and supported by a global sales force and clinical team that provides training and support to hospitals. The company differentiates itself with a broad, multi-specialty product portfolio, an international footprint for manufacturing and distribution, and strong customer service and clinical support. Its goal is to transform patient care by delivering medical solutions that meet hospitals’ and patients’ needs worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South Jordan, Utah

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $381.9 million, up 7.5% year over year.
  • Resilience stent expands Merit’s endoscopy lineup with anti-migration flanges and uncommon sizing.
  • Management expects ViewPoint to become accretive by fiscal 2027 and boost oncology growth.

What critics are saying

  • Tariffs already cut Q1 operating margin by 120 basis points and hit $4.6 million.
  • OEM sales fell 14% from Asia-Pacific weakness and U.S. inventory destocking.
  • Teleflex and Boston Scientific can force pricing concessions across Merit’s interventional and endoscopy channels.

What makes Merit Medical Systems unique

  • Merit sells single-use devices for interventional, diagnostic, and therapeutic procedures globally.
  • Scott R. Ward adds Medtronic and Cardiovascular Systems leadership to Merit’s board.
  • ViewPoint Medical triples oncology addressable procedures through lower-risk breast biopsy localization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Merit Medical Systems who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

8%
The Associated Press
Apr 1st, 2026
Merit Medical acquires View Point Medical for $140M to expand breast cancer detection portfolio

Merit Medical Systems has acquired View Point Medical for approximately $140 million, expanding its therapeutic oncology portfolio. The California-based company manufactures the OneMark Detection Imaging System and tissue markers for breast and soft tissue tumour localisation. Merit paid $90 million in cash at closing, with two deferred payments of $25 million each scheduled over the next two years. The acquisition targets an estimated 1.3 million biopsy procedures annually in the United States. View Point's ultrasound-enhanced technology will complement Merit's existing SCOUT platform, offering physicians more localisation options during diagnostic biopsies and potentially reducing the need for separate pre-surgery procedures. For 2026, the acquisition is projected to contribute $2 million to $4 million in revenue. Merit expects revenue of $14 million to $16 million in 2027, with OneMark sales growing at least 20% annually.

PR Newswire
Mar 24th, 2026
Medtronic expands pain portfolio with FDA-cleared ViaVerte basivertebral nerve ablation system

Medtronic has entered into a distribution agreement with Merit Medical Systems to offer the ViaVerte system, an FDA-cleared basivertebral nerve ablation treatment for chronic vertebrogenic lower back pain. The minimally invasive, implant-free system features a physician-controlled steerable mechanism for precise nerve targeting. ViaVerte, which will be available later this year, offers same-day outpatient procedures for patients suffering from chronic lower back pain caused by damaged vertebral endplates. According to the American Chronic Pain Association, one in three Americans suffer from chronic pain. The agreement expands Medtronic's pain interventions portfolio, which includes spinal cord stimulation, vertebral augmentation and targeted drug delivery. Merit Medical currently supplies Medtronic with inflation syringes and steerable balloon catheters for vertebral compression fracture treatments.

Yahoo Finance
Mar 16th, 2026
Merit Medical launches Resilience esophageal stent with anti-migration design for cancer treatment

Merit Medical Systems has launched the Resilience Through-the-Scope Esophageal Stent in the US, designed to treat esophageal fistulas and strictures caused by malignant tumours. The stent features proprietary anti-migration flanges to prevent movement and is designed to demonstrate the greatest migration resistance amongst currently available TTS stents. A single-handed deployment system enables precise placement, whilst unique sizing options — 14mm x 50mm, 17mm x 50mm, and 20mm x 50mm — address various clinical needs unavailable elsewhere. Esophageal cancer is the sixth most common cause of cancer deaths globally. The new stent joins Merit's endoscopy portfolio, offering physicians enhanced control for treating patients experiencing difficulty swallowing, regurgitation and chest pain caused by esophageal narrowing.

Yahoo Finance
Mar 16th, 2026
Wells Fargo downgrade triggers institutional selling in Merit Medical Systems despite $1.61B revenue guidance

Merit Medical Systems has faced pressure following a Wells Fargo downgrade and subsequent institutional selling, creating a disconnect between market sentiment and the company's fundamentals. The medical device supplier maintains solid operations despite the negative mood shift. Merit recently issued 2026 revenue guidance of $1.610 billion to $1.630 billion, implying mid-single-digit growth despite current headwinds including delayed WRAPSODY CIE reimbursement and higher operating expenses. The company's narrative projects $1.8 billion revenue and $197.2 million earnings by 2028, requiring 7% annual revenue growth. Key risks include continued weakness in China and volume-based purchasing pressure. Simply Wall St Community members currently value the stock between $82.26 and $103.55, suggesting potential upside of up to 48% from current levels.

Yahoo Finance
Feb 26th, 2026
Merit Medical Q4 earnings beat estimates as revenues rise 11% to $394M

Merit Medical Systems reported fourth-quarter 2025 adjusted earnings per share of $1.04, up 12% year over year and beating the Zacks Consensus Estimate by 8.3%. GAAP EPS was 63 cents, up 37% year over year. Fourth-quarter revenues reached $393.9 million, up 11% on a reported basis and topping the consensus estimate by 0.8%. At constant exchange rate, revenues increased 10%, with organic growth of 6.8%. For the full year, adjusted EPS improved 11% to $3.83, whilst total revenues rose 12% to $1.52 billion on a reported basis. US sales grew 11.6% to $238.2 million, and international sales increased 9.9% to $155.7 million. The Cardiovascular segment, which accounts for the majority of revenue, grew 11% to $373.9 million.

INACTIVE